Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed Non-alcoholic Steatohepatitis (NASH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Aug 2025 According to a Metavia media release, the company is currently working to schedule an end-of-Phase 2 meeting with the FDA.
04 Aug 2025 According to a Metavia media release, following positive results from this trial the company formed a research collaboration with Syntekabio,to identify additional disease targets and optimize the therapeutic profile of DA-1241.
07 May 2025 According to a Metavia media release, data from this study findings from this study will be reviewed at end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2025."

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com